Imaging of salivary gland cancers derived from a sublingual gland herniated into the submandibular space: a report of three cases
AbstractSublingual gland herniation into the submandibular space through a mylohyoid muscle defect is a common anatomical variation; however, salivary gland cancers that arise from a herniated sublingual gland have not been described yet. Here, we report three patients with salivary gland cancers originating from a herniated sublingual gland. All tumors were detected as palpable submandibular masses, located anterior to the submandibular gland, medial to the mandible, and lateral to the mylohyoid muscle, with contact with the sublingual gland through a mylohyoid muscle defect. Intraoperative findings confirmed that the mas...
Source: Neuroradiology - April 19, 2024 Category: Radiology Source Type: research
Cancers, Vol. 16, Pages 1205: Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers
Miki Takahara
Salivary gland cancer (SGC) is rare and comprises over 20 histological subtypes. Recently, clinical experience regarding immunotherapies for SGCs has been accumulating, yet their efficacy remains controversial. Understanding the tumor microenvironment (TME), including the expression of immune checkpoint molecules in SGC, is crucial to optimizing immunotherapy. In this review, we demonstrate that high-grade mucoepidermoid carcinoma and salivary duct carcinoma generally exhibit immune-hot TME with high immune cell infiltration, frequent genetic mutations, and robust immune checkpoint molecule expression. In...
Source: Cancers - March 19, 2024 Category: Cancer & Oncology Authors: Ryosuke Sato Hidekiyo Yamaki Hiroki Komatsuda Risa Wakisaka Takahiro Inoue Takumi Kumai Miki Takahara Tags: Review Source Type: research
Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers
Malignant salivary gland cancers (SGC) are rare tumors of the head and neck with no approved therapeutics in the recurrent and/or metastatic setting. The most common histology is adenoid cystic carcinoma (ACC) and the median progression free survival (mPFS) in patients with untreated disease is 2.8 months (mo). MDM2 gene amplifications are common in these tumors and preclinical evidence supports the activity of MDM2 inhibitors both as monotherapy (mono) and in combination (combo) with chemotherapy. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Pearson, J. Muzaffar, K. Kirtane, E. Bellile, K. Suresh, A.J. Rosenberg, F. Worden, C.H. Chung, E.E. Vokes, C. Brenner, J.B. McHugh, Y. Zhai, T. Fu, R. Winkler, P.L. Swiecicki Tags: 8 Source Type: research
Expression of Circulating Prostate-specific Membrane Antigen Extracellular Vesicles in Blood of Patients with Recurrent and Metastatic Salivary Gland Cancer
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein known to be overexpressed in prostate cancer and certain types of salivary gland cancer (SGC). Extracellular vesicles (EVs) are membrane-bound vesicles released from cells that are emerging as a promising blood biomarker for disease monitoring. The purpose of this exploratory analysis is to determine if circulating PSMA EVs can be detected in patients with recurrent or metastatic (R/M) SGC and to explore whether the direction of PSMA EV change correlates with tumor volume change. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K. Price, P.W. McGarrah, E. Horjeti, N.R. Foster, E.J. Asmus, B. Baral, H. Fuentes Bayne, C. Fazer-Posorske, B.J. Burkett, S.C. Lester, D.M. Routman, F. Lucien-Matteoni Tags: 241 Source Type: research
Molecular profiling and the impact of treatment on outcomes in adenoid cystic carcinoma (ACC) type-I and II
CONCLUSIONS: We confirmed the previously reported associations with MYC and TP63 in the prognostically relevant subgroups of ACC-I and II, respectively, and report immunologic differences among these subtypes. Survival outcomes are comparatively worse in ACC-I regardless of treatment type.PMID:38416410 | DOI:10.1158/1078-0432.CCR-23-3182 (Source: Cell Research)
Source: Cell Research - February 28, 2024 Category: Cytology Authors: Glenn J Hanna Punita Grover Andrew Elliott Julie McGrath Joanne Xiu Ammar Sukari Jennifer M Johnson Trisha Wise-Draper Source Type: research
Molecular profiling and the impact of treatment on outcomes in adenoid cystic carcinoma (ACC) type-I and II
CONCLUSIONS: We confirmed the previously reported associations with MYC and TP63 in the prognostically relevant subgroups of ACC-I and II, respectively, and report immunologic differences among these subtypes. Survival outcomes are comparatively worse in ACC-I regardless of treatment type.PMID:38416410 | DOI:10.1158/1078-0432.CCR-23-3182 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 28, 2024 Category: Cancer & Oncology Authors: Glenn J Hanna Punita Grover Andrew Elliott Julie McGrath Joanne Xiu Ammar Sukari Jennifer M Johnson Trisha Wise-Draper Source Type: research
Cancers, Vol. 16, Pages 970: Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?
Maiolino
Fortunato Ciardiello
Alessia Zotta
Salvatore Alfieri
Franco Ionna
Salivary gland carcinomas (SGCs) are rare neoplasms, representing less than 10% of all head and neck tumors, but they are extremely heterogeneous from the histological point of view, their clinical behavior, and their genetics. The guidelines regarding their treatment include surgery in most cases, which can also play an important role in oligometastatic disease. Where surgery cannot be used, systemic therapy comes into play. Systemic therapy for many years has been represented by polychemotherapy, but recently, with the affirmation of ...
Source: Cancers - February 28, 2024 Category: Cancer & Oncology Authors: Francesco Perri Roberta Fusco Francesco Sabbatino Morena Fasano Alessandro Ottaiano Marco Cascella Maria Luisa Marciano Monica Pontone Giovanni Salzano Maria Elena Maiello Massimo Montano Ester Calogero Roberta D ’Aniello Piera Maiolino Fortunato Ciardi Tags: Review Source Type: research
Anti-NOTCH1 therapy with OMP-52 M51 inhibits salivary adenoid cystic carcinoma by depressing epithelial-mesenchymal transition (EMT) process and inducing ferroptosis
Toxicol Appl Pharmacol. 2024 Jan 20:116825. doi: 10.1016/j.taap.2024.116825. Online ahead of print.ABSTRACTSalivary adenoid cystic carcinoma (ACC) is a common type of salivary gland cancer, and the mechanisms underlying its progression still remain poorly understood without efficient therapies. NOTCH1, an evolutionally conserved cell-cell signaling pathway, is involved in the progression of ACC. In our study, we attempted to explore whether NOTCH1 suppression using the monoclonal anti-NOTCH1 antibody OMP-52 M51 could be of potential for ACC treatment. Here, we identified NOTCH1 elevation in human ACC tissues compared with ...
Source: Toxicology and Applied Pharmacology - January 22, 2024 Category: Toxicology Authors: Ran Li Zelong Hu Quanxin Qiao Die Zhou Minglei Sun Source Type: research
Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer
CONCLUSIONS: Brachytherapy as a sole modality, was retrospectively proven effective and safe in the management of inoperable SGCs and was beneficial in multiple irradiation and pain control.PMID:38043903 | DOI:10.1016/j.radonc.2023.110022 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 3, 2023 Category: Radiology Authors: Zhong Yiwei Lyu Xiaoming Huang Mingwei Zheng Lei Liu Shuming Shi Yan Wu Wenjie Zhang Jie Zhang Jianguo Source Type: research
Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer
CONCLUSIONS: Brachytherapy as a sole modality, was retrospectively proven effective and safe in the management of inoperable SGCs and was beneficial in multiple irradiation and pain control.PMID:38043903 | DOI:10.1016/j.radonc.2023.110022 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 3, 2023 Category: Radiology Authors: Zhong Yiwei Lyu Xiaoming Huang Mingwei Zheng Lei Liu Shuming Shi Yan Wu Wenjie Zhang Jie Zhang Jianguo Source Type: research
Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer
CONCLUSIONS: Brachytherapy as a sole modality, was retrospectively proven effective and safe in the management of inoperable SGCs and was beneficial in multiple irradiation and pain control.PMID:38043903 | DOI:10.1016/j.radonc.2023.110022 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 3, 2023 Category: Radiology Authors: Yiwei Zhong Xiaoming Lyu Mingwei Huang Lei Zheng Shuming Liu Yan Shi Wenjie Wu Jie Zhang Jianguo Zhang Source Type: research
Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer
CONCLUSIONS: Brachytherapy as a sole modality, was retrospectively proven effective and safe in the management of inoperable SGCs and was beneficial in multiple irradiation and pain control.PMID:38043903 | DOI:10.1016/j.radonc.2023.110022 (Source: Cancer Control)
Source: Cancer Control - December 3, 2023 Category: Cancer & Oncology Authors: Zhong Yiwei Lyu Xiaoming Huang Mingwei Zheng Lei Liu Shuming Shi Yan Wu Wenjie Zhang Jie Zhang Jianguo Source Type: research
Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer
Salivary gland cancers (SGCs) are rare and heterogeneous, accounting for less than 5% of head and neck malignancies and comprise over 20 distinct subtypes. These tumours vary in histology, behaviour, and treatment response, and therefore present challenges in clinical decisions. Surgery with or without adjuvant radiotherapy remains the first-line treatment while unmet needs exist [1,2]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - December 1, 2023 Category: Radiology Authors: Zhong Yiwei, Lyu Xiaoming, Huang Mingwei, Zheng Lei, Liu Shuming, Shi Yan, Wu Wenjie, Zhang Jie, Zhang Jianguo Tags: Original Article Source Type: research
Treatment and outcomes of minor salivary gland cancers of the larynx and trachea: a systematic review
CONCLUSIONS: In case of MiSGC of the larynx and trachea, surgery remains the mainstay of treatment. Adjuvant treatments are frequently delivered. Survival estimates are good overall, but highly heterogeneous.PMID:37814980 | DOI:10.14639/0392-100X-N2635 (Source: Acta Otorhinolaryngologica Italica)
Source: Acta Otorhinolaryngologica Italica - October 10, 2023 Category: ENT & OMF Authors: Claudia Montenegro Davide Mattavelli Davide Lancini Alberto Paderno Elisa Marazzi Vittorio Rampinelli Michele Tomasoni Cesare Piazza Source Type: research
